of multiple interventions within a single overarching protocol. For clinical operations, regulatory affairs, and medical affairs professionals working on device and combination product trials in the US, UK, and EU, understanding how to integrate platform trial design into global regulatory strategies is essential. This article provides a detailed step-by-step compliance guide addressing the regulatory frameworks, operational considerations, and best practices necessary to successfully implement platform trial designs while ensuring adherence to FDA, EMA, and MHRA expectations. The guidance also references relevant international standards such as ICH and WHO to support harmonized global trial conduct.

Context and Core Definitions for Device & Combination Product Regulations and Platform Trial Design

To effectively integrate platform trial design into device and combination product regulations, it is critical first to define foundational terms and concepts. Platform trial design is a master protocol framework that allows multiple interventions to be tested simultaneously or sequentially against a shared control group within a perpetual or adaptive trial infrastructure. This design contrasts with traditional two-arm trials by offering flexibility to add or drop treatment arms based on interim analyses, thus accelerating development timelines and resource optimization.

Device and combination products are regulated entities that combine drugs, devices, and/or biological products. Examples include drug-eluting stents, combination inhalers, or drug-device diagnostic platforms. Regulatory classification depends on the primary mode of action (PMOA), which determines whether the product is regulated predominantly as a drug, device, or biologic. Understanding this classification is essential for platform trials involving these products, as it dictates the applicable regulatory pathways and compliance requirements.

In clinical trials, platform designs have been increasingly applied in complex therapeutic areas, such as oncology and infectious diseases, exemplified by trials like the Navigator trial and the Pfizer vaccine trials. Similarly, the katherine clinical trial and sting agonist clinical trial models illustrate how adaptive platform designs can be tailored for combination products. For regulatory compliance, sponsors must ensure clarity in protocol design, risk mitigation strategies, and data integrity measures to satisfy authorities across regions.

Regulatory frameworks in the US, EU, and UK provide specific guidance on device and combination product trials, but platform trial design introduces additional complexity requiring harmonized interpretation. This article will unpack these regulatory expectations and operationalize them into actionable steps for global clinical teams.

Regulatory and GCP Expectations in US, EU, and UK

Regulatory agencies in the US, EU, and UK have established comprehensive frameworks governing device and combination product clinical trials, with additional considerations for platform trial designs.

United States (FDA): The FDA regulates combination products under 21 CFR Part 3, with the Office of Combination Products coordinating review assignments. Device components are regulated under 21 CFR Parts 800-1299, while drugs and biologics have separate regulatory pathways. The FDA’s guidance documents on master protocols and adaptive designs provide recommendations for platform trial design implementation, emphasizing robust statistical planning, pre-specified adaptation rules, and comprehensive risk assessments. Good Clinical Practice (GCP) compliance is mandated under 21 CFR Part 312 and Part 812 for drug and device investigations, respectively.

European Union (EMA/EU-CTR): The EU Clinical Trials Regulation (EU-CTR 536/2014) harmonizes clinical trial requirements across member states, including device and combination product trials. The EMA provides scientific advice on combination products and adaptive platform trials, referencing ICH E6(R3) and E9(R1) guidelines for trial design and data integrity. The Medical Device Regulation (MDR 2017/745) governs device components, with notified bodies involved in conformity assessments. Sponsors must ensure compliance with both MDR and EU-CTR provisions, particularly regarding safety reporting, informed consent, and trial transparency.

United Kingdom (MHRA): Post-Brexit, the MHRA regulates clinical trials under the UK Clinical Trial Regulations 2004 (as amended) and the UK Medical Devices Regulations 2002 (as amended). The MHRA endorses ICH GCP guidelines and has issued specific guidance on adaptive and platform trials, highlighting the importance of clear protocol amendments and regulatory notifications. Combination product trials require coordination between MHRA’s device and medicinal product divisions to ensure comprehensive oversight.

Across all regions, adherence to ICH E6(R3) Good Clinical Practice and ICH E8(R1) General Considerations for Clinical Trials is mandatory. Additionally, WHO and CIOMS guidelines provide ethical frameworks supporting platform trial designs, especially in vulnerable populations or urgent public health scenarios.

Practical Design and Operational Considerations for Platform Trial Design in Device and Combination Product Trials

Implementing platform trial design within device and combination product trials demands meticulous planning and operational coordination. The following step-by-step guidance outlines critical considerations:

1. Define the Master Protocol Structure: Develop a comprehensive master protocol that outlines the overall trial framework, including objectives, eligibility criteria, treatment arms, and adaptive features. Clearly specify how device and combination product components integrate within the platform, including their PMOA and regulatory classification.
2. Statistical Planning and Interim Analyses: Collaborate with biostatisticians to design robust statistical methodologies accommodating multiple arms and adaptive decision rules. Pre-specify criteria for adding or dropping arms, sample size re-estimation, and control group management to maintain type I error control and data integrity.
3. Regulatory Engagement: Engage early with regulatory authorities (FDA, EMA, MHRA) via scientific advice or pre-submission meetings to align on platform trial design elements, especially for combination products. Address device-specific requirements such as usability testing, risk management, and device accountability.
4. Protocol Content and Amendments: Ensure the protocol contains detailed descriptions of device usage, combination product handling, and safety monitoring plans. Establish clear processes for protocol amendments to add or remove treatment arms, with timely regulatory submissions and ethics committee notifications.
5. Operational Workflow and Roles: Define roles and responsibilities among sponsors, Contract Research Organizations (CROs), investigators, and site staff. For example, sponsors oversee regulatory compliance and data monitoring; CROs manage trial logistics; principal investigators ensure protocol adherence and subject safety; site staff handle device handling and data collection.
6. Training and Documentation: Develop targeted training programs covering platform trial design principles, device-specific procedures, and combination product handling. Maintain comprehensive documentation including device master files, investigational device exemption (IDE) approvals, and device accountability logs.
7. Data Management and Safety Monitoring: Implement electronic data capture systems capable of handling complex platform data structures. Establish Data Monitoring Committees (DMCs) with expertise in adaptive designs and device safety to oversee interim analyses and risk mitigation.

Examples such as the katherine clinical trial and the sting agonist clinical trial demonstrate successful integration of platform designs in combination product development, highlighting the importance of adaptive operational strategies and proactive regulatory communication.

Common Pitfalls, Inspection Findings, and How to Avoid Them

Regulatory inspections and audits frequently identify recurring issues in platform trial designs involving device and combination products. Awareness and mitigation of these pitfalls are critical for compliance and trial success:

• Insufficient Protocol Clarity: Ambiguous definitions of adaptive rules, device handling procedures, or combination product roles can lead to protocol deviations and regulatory queries. Prevention requires detailed protocol drafting and internal reviews.
• Inadequate Regulatory Submissions for Amendments: Failure to timely notify authorities of protocol amendments adding or removing treatment arms may result in non-compliance with regulatory timelines. Implement SOPs to track and submit amendments promptly.
• Incomplete Device Accountability: Poor documentation of device receipt, usage, and return can compromise data integrity and patient safety. Establish rigorous device tracking systems and train site personnel accordingly.
• Data Management Challenges: Complex data structures in platform trials can cause data inconsistencies or delays in interim analyses. Utilize validated electronic systems and conduct regular data quality checks.
• Insufficient Training: Lack of comprehensive training on platform trial design and combination product specifics leads to protocol non-adherence and safety risks. Develop role-specific training modules and refresher sessions.

Addressing these pitfalls proactively through SOPs, quality assurance audits, and continuous education reduces inspection findings and enhances trial integrity.

US vs EU vs UK Nuances and Real-World Case Examples

While the US, EU, and UK share common regulatory principles for device and combination product trials, several nuances affect platform trial design implementation:

• Regulatory Classification: The FDA’s Office of Combination Products provides a centralized classification process, whereas in the EU, device and drug components are regulated under separate frameworks (MDR and EU-CTR), requiring coordination with notified bodies. The UK MHRA follows a hybrid approach post-Brexit, necessitating dual compliance for some products.
• Submission Processes: The FDA allows for pre-IND and IDE submissions specific to combination products, while the EU requires Clinical Trial Applications (CTA) under EU-CTR and conformity assessments under MDR. The MHRA requires Clinical Trial Authorisation (CTA) with device-specific documentation.
• Adaptive Design Acceptance: The FDA has published detailed guidance on master protocols and adaptive designs, emphasizing statistical rigor. EMA and MHRA encourage early scientific advice to ensure adaptive elements are acceptable, with EMA providing reflection papers on complex trial designs.

Case Example 1: A global platform trial evaluating a drug-device combination for oncology incorporated adaptive arms based on biomarker stratification. Early engagement with FDA and EMA scientific advice enabled alignment on statistical methods and device risk management, facilitating synchronized submissions and approvals.

Case Example 2: A UK-based platform trial faced challenges with MHRA regarding device classification and reporting timelines. The sponsor implemented enhanced SOPs for device accountability and expedited amendment submissions, resolving compliance issues and improving inspection readiness.

Multinational teams can harmonize approaches by establishing cross-functional regulatory working groups, leveraging shared master protocols, and aligning training programs to accommodate regional differences.

Implementation Roadmap and Best-Practice Checklist

To operationalize platform trial design within device and combination product regulations, clinical teams should follow this stepwise roadmap:

1. Initiate Early Regulatory Engagement: Schedule pre-submission meetings with FDA, EMA, and MHRA to discuss platform design and combination product classification.
2. Develop a Comprehensive Master Protocol: Incorporate detailed adaptive design features, device handling procedures, and safety monitoring plans.
3. Establish Statistical Analysis Plan (SAP): Define interim analysis rules, control arm management, and multiplicity adjustments.
4. Create SOPs for Protocol Amendments: Ensure timely regulatory submissions and ethics notifications for changes in treatment arms.
5. Implement Device Accountability Systems: Track device inventory, usage, and returns with audit trails.
6. Deliver Role-Specific Training: Cover platform trial concepts, device procedures, and regulatory compliance requirements.
7. Set Up Data Monitoring Committees: Include expertise in adaptive designs and device safety for ongoing oversight.
8. Conduct Regular Quality Audits: Review protocol adherence, data integrity, and regulatory compliance.

Below is a checklist summarizing essential best practices:

• Early and continuous regulatory dialogue across US, EU, and UK agencies.
• Clear master protocol with adaptive design and device-specific content.
• Robust statistical planning with pre-defined adaptation criteria.
• Comprehensive SOPs for amendment management and device accountability.
• Targeted training programs for all clinical trial personnel.
• Validated data capture and monitoring systems tailored for platform trials.
• Proactive quality assurance and audit processes.

Comparison of Regulatory Expectations for Platform Trial Design in Device & Combination Product Trials: US, EU, and UK

Aspect	US (FDA)	EU (EMA/EU-CTR)	UK (MHRA)
Regulatory Classification	Office of Combination Products coordinates; PMOA determines lead center	Separate MDR and EU-CTR pathways; notified body involvement for devices	Hybrid approach; coordination between medicinal and device divisions
Submission Requirements	IND/IDE submissions; master protocol guidance available	CTA under EU-CTR; conformity assessment under MDR	CTA with device documentation; post-Brexit regulatory framework
Adaptive Design Guidance	Detailed FDA guidance on master protocols and adaptive trials	Scientific advice encouraged; reflection papers on complex designs	Early engagement recommended; emphasis on protocol amendments
Device Accountability	Strict tracking per 21 CFR Part 812	Device-specific reporting per MDR requirements	Device handling and reporting per UK MDR
GCP Compliance	21 CFR Parts 312, 812; ICH E6(R3)	EU-CTR; ICH E6(R3); MDR	UK Clinical Trial Regulations; ICH E6(R3)

Key Takeaways for Clinical Trial Teams

• Develop a detailed master protocol incorporating adaptive platform trial design elements and device-specific procedures to ensure regulatory clarity and operational feasibility.
• Engage early and continuously with FDA, EMA, and MHRA to align on regulatory expectations and minimize compliance risks during trial conduct.
• Implement robust SOPs and targeted training focusing on protocol amendments, device accountability, and data integrity to prevent common inspection findings.
• Harmonize global trial strategies by understanding and addressing US, EU, and UK regulatory nuances, leveraging cross-functional collaboration and shared best practices.